Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Pharmakologie (14 Abbildungen)
Übersicht


Zum ersten Bild Abb. 7: Telmisartan - PPAR-Gamma Abb. 8: SBD - DBD Abb. 9: Normaldosierung Abb. 10: Dosierung - Alter - Geschlecht Abb. 11: Telmisartan - Harnausscheidung Aktuelles Bild - Abb. 12: Dosierung - Nephropathien Abb. 13: Telmisartan - Wechselwirkung Abb. 14: Pharmakologie: Zusammenfassung
Abbildung 12: Dosierung - Nephropathien
Because telmisartan is 99.5% bound to serum protein, it is not dialysable, and as a result there is no requirement for post-dialysis supplementation.1 Valsartan and eprosartan show notably lower binding (95 % and 90 %, respectively).1 Telmisartan has been shown to reduce blood pressure in patients with renal disease in the Efficacy and Safety in Patients with Renal Impairment treated with Telmisartan (ESPRIT) study.2 ESPRIT was a 12-week, open-label study of telmisartan 40–80 mg in 82 patients with hypertension (DBP 90–109 mmHg) and chronic mild/moderate (GFR 30–74 ml/min/1.73 m2) or severe renal impairment (GFR <30 ml/min/1.73 m2), or requiring maintenance haemodialysis. There was greater effect in patients with greater renal impairment (a common finding in this patient population). 1. Song JC, White CM. Olmesartan medoxomil (CS-866). An angiotensin II receptor blocker for treatment of hypertension. Formulary 2001; 36: 487-499. 2. Sharma AM, et al. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol 2005; 63: 250–257.
 
Dosierung - Nephropathien
Vorheriges Bild Nächstes Bild   


Abbildung 12: Dosierung - Nephropathien
Because telmisartan is 99.5% bound to serum protein, it is not dialysable, and as a result there is no requirement for post-dialysis supplementation.1 Valsartan and eprosartan show notably lower binding (95 % and 90 %, respectively).1 Telmisartan has been shown to reduce blood pressure in patients with renal disease in the Efficacy and Safety in Patients with Renal Impairment treated with Telmisartan (ESPRIT) study.2 ESPRIT was a 12-week, open-label study of telmisartan 40–80 mg in 82 patients with hypertension (DBP 90–109 mmHg) and chronic mild/moderate (GFR 30–74 ml/min/1.73 m2) or severe renal impairment (GFR <30 ml/min/1.73 m2), or requiring maintenance haemodialysis. There was greater effect in patients with greater renal impairment (a common finding in this patient population). 1. Song JC, White CM. Olmesartan medoxomil (CS-866). An angiotensin II receptor blocker for treatment of hypertension. Formulary 2001; 36: 487-499. 2. Sharma AM, et al. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol 2005; 63: 250–257.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung